DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier

Core Insights - Day One Biopharmaceuticals (DAWN) has entered into a definitive agreement with Servier for the acquisition of all outstanding shares at $21.50 each, valuing the deal at approximately $2.5 billion [1][7] Group 1: Acquisition Details - The acquisition will enable Servier to add Ojemda, DAWN's first marketed drug, which received accelerated FDA approval in 2024 for treating relapsed or refractory pediatric low-grade glioma (pLGG) [2] - The deal is expected to close in the second quarter, with Servier planning to finance the transaction through existing cash and investments [3] Group 2: Financial Performance - Following the acquisition announcement, DAWN's stock price surged nearly 66%, and the stock has increased by 127% year-to-date compared to the industry's 4% growth [4] Group 3: Strategic Rationale - Servier's interest in DAWN aligns with its 2030 goal to develop innovative treatments across various therapeutic areas, including oncology [6] - Ojemda reported sales of $155.4 million for the full year 2025, reflecting a 172% year-over-year increase, with projected sales for 2026 estimated between $225 million and $250 million [6] Group 4: Portfolio Expansion - In addition to Ojemda, the acquisition will enhance Servier's oncology portfolio with two early-stage antibody drug conjugate (ADC) candidates, emiltatug ledadotin (emi-le) and DAY301, which are currently in separate early-stage studies [8] - This acquisition is part of Servier's broader strategy, which includes previous deals in the oncology space, such as licensing agreements with Black Diamond Therapeutics and Ideaya Biosciences [9]